Anja Karlstaedt1, Radhika Khanna2, Manoj Thangam3, Heinrich Taegtmeyer1. 1. From the Division of Cardiology, Department of Internal Medicine, McGovern Medical School at The University of Texas Health Science Center at Houston (A.K., H.T.). 2. Ross University School of Medicine, Miramar, FL (R.K.). 3. Department of Cardiology, Washington University School of Medicine in St. Louis, MO (M.T.).
Abstract
RATIONALE: Metabolic and structural remodeling is a hallmark of heart failure. This remodeling involves activation of the mTOR (mammalian target of rapamycin) signaling pathway, but little is known on how intermediary metabolites are integrated as metabolic signals. OBJECTIVE: We investigated the metabolic control of cardiac glycolysis and explored the potential of glucose 6-phosphate (G6P) to regulate glycolytic flux and mTOR activation. METHODS AND RESULTS: We developed a kinetic model of cardiomyocyte carbohydrate metabolism, CardioGlyco, to study the metabolic control of myocardial glycolysis and G6P levels. Metabolic control analysis revealed that G6P concentration is dependent on phosphoglucose isomerase (PGI) activity. Next, we integrated ex vivo tracer studies with mathematical simulations to test how changes in glucose supply and glycolytic flux affect mTOR activation. Nutrient deprivation promoted a tight coupling between glucose uptake and oxidation, G6P reduction, and increased protein-protein interaction between hexokinase II and mTOR. We validated the in silico modeling in cultured adult mouse ventricular cardiomyocytes by modulating PGI activity using erythrose 4-phosphate. Inhibition of glycolytic flux at the level of PGI caused G6P accumulation, which correlated with increased mTOR activation. Using click chemistry, we labeled newly synthesized proteins and confirmed that inhibition of PGI increases protein synthesis. CONCLUSIONS: The reduction of PGI activity directly affects myocyte growth by regulating mTOR activation.
RATIONALE: Metabolic and structural remodeling is a hallmark of heart failure. This remodeling involves activation of the mTOR (mammalian target of rapamycin) signaling pathway, but little is known on how intermediary metabolites are integrated as metabolic signals. OBJECTIVE: We investigated the metabolic control of cardiac glycolysis and explored the potential of glucose 6-phosphate (G6P) to regulate glycolytic flux and mTOR activation. METHODS AND RESULTS: We developed a kinetic model of cardiomyocyte carbohydrate metabolism, CardioGlyco, to study the metabolic control of myocardial glycolysis and G6P levels. Metabolic control analysis revealed that G6P concentration is dependent on phosphoglucose isomerase (PGI) activity. Next, we integrated ex vivo tracer studies with mathematical simulations to test how changes in glucose supply and glycolytic flux affect mTOR activation. Nutrient deprivation promoted a tight coupling between glucose uptake and oxidation, G6P reduction, and increased protein-protein interaction between hexokinase II and mTOR. We validated the in silico modeling in cultured adult mouse ventricular cardiomyocytes by modulating PGI activity using erythrose 4-phosphate. Inhibition of glycolytic flux at the level of PGI caused G6P accumulation, which correlated with increased mTOR activation. Using click chemistry, we labeled newly synthesized proteins and confirmed that inhibition of PGI increases protein synthesis. CONCLUSIONS: The reduction of PGI activity directly affects myocyte growth by regulating mTOR activation.
Authors: Ralph J DeBerardinis; Anthony Mancuso; Evgueni Daikhin; Ilana Nissim; Marc Yudkoff; Suzanne Wehrli; Craig B Thompson Journal: Proc Natl Acad Sci U S A Date: 2007-11-21 Impact factor: 11.205
Authors: Dan Shao; Outi Villet; Zhen Zhang; Sung Won Choi; Jie Yan; Julia Ritterhoff; Haiwei Gu; Danijel Djukovic; Danos Christodoulou; Stephen C Kolwicz; Daniel Raftery; Rong Tian Journal: Nat Commun Date: 2018-07-26 Impact factor: 14.919
Authors: Giovanni E Davogustto; Rebecca L Salazar; Hernan G Vasquez; Anja Karlstaedt; William P Dillon; Patrick H Guthrie; Joseph R Martin; Heidi Vitrac; Gina De La Guardia; Deborah Vela; Aleix Ribas-Latre; Corrine Baumgartner; Kristin Eckel-Mahan; Heinrich Taegtmeyer Journal: J Mol Cell Cardiol Date: 2021-06-01 Impact factor: 5.763
Authors: Hong Zhang; Laween Uthman; Diane Bakker; Sahinda Sari; Sha Chen; Markus W Hollmann; Ruben Coronel; Nina C Weber; Sander M Houten; Michel van Weeghel; Coert J Zuurbier Journal: Front Cardiovasc Med Date: 2020-12-04
Authors: Samprikta Manna; Camino S M Ruano; Jana-Charlotte Hegenbarth; Daniel Vaiman; Shailendra Gupta; Fergus P McCarthy; Céline Méhats; Cathal McCarthy; Clara Apicella; Julia Scheel Journal: Antioxidants (Basel) Date: 2022-03-18
Authors: Kyle S McCommis; Attila Kovacs; Carla J Weinheimer; Trevor M Shew; Timothy R Koves; Olga R Ilkayeva; Dakota R Kamm; Kelly D Pyles; M Todd King; Richard L Veech; Brian J DeBosch; Deborah M Muoio; Richard W Gross; Brian N Finck Journal: Nat Metab Date: 2020-10-26